OTCMKTS:GOVX - Geovax Labs Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0380 0.00 (0.00 %)
(As of 07/22/2018 10:55 AM ET)
Previous Close$0.0380
Today's Range$0.0371 - $0.04
52-Week Range$0.0248 - $0.1049
Volume46,126 shs
Average Volume238,008 shs
Market Capitalization$6.26 million
P/E RatioN/A
Dividend YieldN/A
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; and CaroGen Corporation. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

Receive GOVX News and Ratings via Email

Sign-up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Commercial physical research


Debt-to-Equity Ratio-0.02
Current Ratio0.88
Quick Ratio0.88


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.08 million
Price / Sales5.80
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-1.90


EPS (Most Recent Fiscal Year)($0.03)
Net Income$-2,170,000.00
Net Margins-224.40%
Return on EquityN/A
Return on Assets-320.57%


Outstanding Shares164,740,000
Market Cap$6.26

Geovax Labs (OTCMKTS:GOVX) Frequently Asked Questions

What is Geovax Labs' stock symbol?

Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How were Geovax Labs' earnings last quarter?

Geovax Labs Inc (OTCMKTS:GOVX) announced its quarterly earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.01) earnings per share for the quarter. The biotechnology company earned $0.22 million during the quarter. View Geovax Labs' Earnings History.

When is Geovax Labs' next earnings date?

Geovax Labs is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Geovax Labs.

What is the consensus analysts' recommendation for Geovax Labs?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geovax Labs in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Geovax Labs' key competitors?

Who are Geovax Labs' key executives?

Geovax Labs' management team includes the folowing people:
  • Dr. Robert T. McNally, Pres, CEO & Director (Age 70)
  • Dr. Harriet Latham Robinson, Co-Founder, Chief Scientific Officer Emeritus & Director (Age 80)
  • Mr. Mark W. Reynolds CPA, CFO & Corp. Sec. (Age 56)
  • Dr. Farshad Guirakhoo, Chief Scientific Officer (Age 65)
  • Mr. Donald G. Hildebrand, Founder, Chairman Emeritus and Consultant (Age 77)

Has Geovax Labs been receiving favorable news coverage?

News coverage about GOVX stock has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Geovax Labs earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 44.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Geovax Labs?

Shares of GOVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geovax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $0.0380.

How big of a company is Geovax Labs?

Geovax Labs has a market capitalization of $6.26 million and generates $1.08 million in revenue each year. The biotechnology company earns $-2,170,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. Geovax Labs employs 9 workers across the globe.

How can I contact Geovax Labs?

Geovax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The biotechnology company can be reached via phone at 678-384-7220 or via email at [email protected]

MarketBeat Community Rating for Geovax Labs (OTCMKTS GOVX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  82
MarketBeat's community ratings are surveys of what our community members think about Geovax Labs and other stocks. Vote "Outperform" if you believe GOVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.